In addition, siRNA silencing of TRPV2 reduced the growth and invasion of PC-3 cells in xenograft models of prostate cancer and reduced the expression of invasive markers, MMP2, MMP9, and cathepsin-B [153], suggesting that inhibition of TRPV2 may reduce the aggressive phenotype of prostate cancer. Here, CTSB is linked to prostate carcinoma.